COMMUNIQUÉS West-GlobeNewswire

Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting

05/12/2017 - 13:00

40 mg dose showed statistically significant improvement on Cogscreen objective cognitive measures of attention and memory Two additional self-rated secondary endpoints (CPFQ and QIDS) showed statistically significant [...]

Clementia Announces Date of Corporate Update Conference Call

05/12/2017 - 12:30

MONTREAL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), a clinical-stage biopharmaceutical company, today announced that management will host a conference call and webcast at 8:30 a.m [...]

Clementia Annonce la Date de la Conférence Téléphonique sur sa Mise à Jour Corporative

05/12/2017 - 12:30

MONTRÉAL, 05 déc. 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui que la direction tiendra une conférence téléphonique et [...]

Biodesix Leaders Share Commercial and Pipeline Updates at Annual qPCR and dPCR Congress

05/12/2017 - 12:00

BOULDER, Colo., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Biodesix provided updates and data related to the company’s on-market and in-development liquid biopsy tests at the 2017 qPCR & Digital PCR Congress in London, UK [...]

Transactions in relation to share buyback program

05/12/2017 - 11:18

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

05/12/2017 - 09:05

VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. ( “CTL” ) [...]

Update on NeuroSearch’s business status and future

05/12/2017 - 08:02

Company announcement 5 December 2017 In the annual report for 2016, the Board of Directors informed that the Company would continue the work to dispose its remaining assets and liabilities, and that a sale of the [...]

Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

05/12/2017 - 08:00

THE WOODLANDS, Texas, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that it has entered into a definitive term loan agreement with BioPharma Credit PLC and BioPharma [...]

Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial

05/12/2017 - 07:02

Abu Dhabi, UAE, 5 December 2017 - Once-daily Xultophy ® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by [...]

Probiodrug AG: Probiodrug and Crossbeta Biosciences extend their strategic partnership in the field of Alzheimer's disease biomarkers

05/12/2017 - 07:00

HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), and the [...]

Beleave Receives License to Produce Cannabis Oils from Health Canada

05/12/2017 - 00:18

TORONTO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (" Beleave " or the " Company ") (CSE:BE)( OTCQX:BLEVF) is pleased to announce it has been granted a license by Health Canada to begin commercial production of [...]

Triphase Accelerator to Present Investigational New Drug Enabling Data for TRPH-222

04/12/2017 - 23:35

TORONTO and SOMERSET, N.J., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading [...]

NTS Ventures and IHMA Announce a Collaborative Agreement to Provide an Extensive Suite of Clinical Mycology, Antifungal and Microbiology Laboratory Services to Support Anti-infective Drug Development to the Biopharmaceutical Industry

04/12/2017 - 23:24

SCHAUMBURG, Ill., Dec. 04, 2017 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a full-service [...]

Immunovaccine to Hold Webcast and Conference Call to Discuss Clinical Data From Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

04/12/2017 - 23:05

HALIFAX, Nova Scotia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it will hold a webcast and conference call tomorrow ( [...]

Collegium to License Rights to Commercialize Nucynta Franchise

04/12/2017 - 22:30

Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’s existing [...]

Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04/12/2017 - 22:30

BURLINGTON, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced a grant of inducement stock options to three new employees for an aggregate of 20,500 shares of common [...]

Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting

04/12/2017 - 22:30

DURHAM, N.C., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ) today announced that the Company will present four abstracts, three of which will be oral presentations, with data from Phase 3 [...]

Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

04/12/2017 - 22:29

SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL ), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]

Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

04/12/2017 - 22:05

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc . (Nasdaq: FPRX ), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today [...]